---
title: "Science Sun Pharm issues a profit warning, expecting a net loss of RMB 59.1728 million to RMB 88.7592 million for the fiscal year 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/226119725.md"
description: "Science Sun Pharm released its performance forecast for 2024, expecting a net loss of between 59.1728 million yuan and 88.7592 million yuan, a shift from profit to loss year-on-year. During the reporting period, the company's fair value changes in financial assets and investment income from joint ventures decreased, mainly investing in related fields such as biomedicine and medical devices, with fair value change income and investment income approximately -110 million yuan, a decline of 170%"
datetime: "2025-01-24T08:33:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/226119725.md)
  - [en](https://longbridge.com/en/news/226119725.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/226119725.md)
generator: "portal-rs"
---

# Science Sun Pharm issues a profit warning, expecting a net loss of RMB 59.1728 million to RMB 88.7592 million for the fiscal year 2024

According to the Zhitong Finance APP, Science Sun Pharm (300485.SZ) released its performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company of between 59.1728 million yuan and 88.7592 million yuan, a year-on-year shift from profit to loss.

During the reporting period, the company recognized a decrease in the fair value changes of financial assets and investment income from joint ventures in accordance with the new financial instruments standards compared to the previous period. The company's invested financial assets are mainly in biomedicine, medical devices, and other companies related to its main business, as well as specialized investment funds in the pharmaceutical and health sectors. The fair value change income and investment income for this reporting period is approximately -110 million yuan, representing a decline of about 170%

### Related Stocks

- [300485.CN](https://longbridge.com/en/quote/300485.CN.md)
- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)

## Related News & Research

- [Golf-PGA Tour overhauls post-season, moving to match play format in 2028](https://longbridge.com/en/news/296930417.md)
- [Lenzing shareholders approve EUR 300 million capital increase at extraordinary meeting](https://longbridge.com/en/news/296902548.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [NFL-NFL, NFLPA tighten discipline for repeat player-safety violations](https://longbridge.com/en/news/297094204.md)
- [RCS - ZAGENO - ZAGENO and ORO Labs Partnership](https://longbridge.com/en/news/297046609.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**